WUXI BIO(02269),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02269 WUXI BIO

Not Yet Opened 03-17 16:08:14

34.940

+0.080

+0.23%

High36.280	Low34.820	Vol20.78M
Open35.000	D1 Closing34.860	Amplitude4.19%
Mkt Cap144.58B	Tradable Cap144.58B	Total Shares4.14B
T/O734.84M	T/O Rate0.50%	Tradable Shares4.14B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02269","market":"HK","secType":"STK","nameCN":"WUXI BIO","latestPrice":34.94,"timestamp":1773734894002,"preClose":34.86,"halted":0,"volume":20777881,"delay":0,"changeRate":0.0022948938611588726,"floatShares":4138000000,"shares":4138000000,"eps":0.784646,"marketStatus":"Not Yet Opened","change":0.08,"latestTime":"03-17 16:08:14","open":35,"high":36.28,"low":34.82,"amount":734836687,"amplitude":0.041882,"askPrice":34.96,"askSize":196500,"bidPrice":34.94,"bidSize":53000,"shortable":3,"etf":0,"ttmEps":1.083128,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773797400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1497283200000,"exchange":"SEHK","adjPreClose":34.86,"openAndCloseTimeList":[[1773711000000,1773720000000],[1773723600000,1773734400000]],"volumeRatio":1.04716073476709,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"WXB.HK","impliedVol":0.5188,"impliedVolPercentile":0.3293},"requestUrl":"/m/hq/s/02269/tweets","defaultTab":"tweets","newsList":[{"id":"2620942534","title":"WuXi XDC Cayman says BioDlink tender offer turns unconditional after 60% share acceptances","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942534","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620942534?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:34","pubTimestamp":1773743640,"startTime":"0","endTime":"0","summary":"WuXi XDC’s offer to buy the remaining shares of BioDlink reached the acceptance threshold after receiving valid acceptances for 463.67 million shares, representing 60% of BioDlink’s voting rights. The related offer to cancel BioDlink’s outstanding share options also became unconditional, with acceptances covering 6.51 million options, or 85.33% of the total. The offers are scheduled to remain open for acceptance until 31 March 2026. Cash settlement for valid acceptances is expected to be made no later than seven business days after the later of the unconditional date and receipt of completed acceptance documents.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi XDC Cayman Inc. published the original content used to generate this new","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL10xgwd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B0JY6N72.USD","LU2039709279.SGD","LU0819121731.USD","LU0348825331.USD","LU0359202008.SGD","LU0516423174.USD","LU1688375341.USD","BK1576","BK1141","LU0326950275.SGD","LU0588546209.SGD","BK1589","LU0043850808.USD","LU1242518857.USD","LU0456827905.SGD","LU0856984785.SGD","LU0516422952.EUR","BK1610","LU0039217434.USD","LU1242518931.SGD","LU0417516738.SGD","LU0708995583.HKD","SG9999014674.SGD","LU0823426308.USD","LU0348735423.USD","LU0307460666.USD","02268","LU0516422440.USD","SG9999002463.SGD","LU0051755006.USD","LU0181495838.USD","LU0140636845.USD","LU0327786744.USD","LU0456846285.SGD","LU2488822045.USD","LU0359201612.USD","LU3063872942.SGD","LU0979878070.USD","LU0516423091.SGD","LU1880383366.USD","LU1720050803.USD","LU0823426480.USD","SG9999002562.SGD","LU0320764599.SGD","LU0417516902.SGD","02269","LU1794554557.SGD","LU0572944931.SGD","LU0052750758.USD","LU0516422366.SGD"],"gpt_icon":0},{"id":"1156982969","title":"HK Movers | Biotech Stocks Jump. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1156982969","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156982969?lang=en_us&edition=fundamental","pubTime":"2026-03-17 10:41","pubTimestamp":1773715275,"startTime":"0","endTime":"0","summary":"Biotech stocks jumped in Hong Kong. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","02269","06606","09688","03759","01672","09995","02137","09966","03347","02268","09606","06978"],"gpt_icon":0},{"id":"2620188214","title":"A Look At WuXi Biologics (SEHK:2269) Valuation After Earendil Deal And Biopharma Excellence Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2620188214","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620188214?lang=en_us&edition=fundamental","pubTime":"2026-03-17 06:18","pubTimestamp":1773699524,"startTime":"0","endTime":"0","summary":"WuXi Biologics (Cayman) (SEHK:2269) is back in focus after two recent developments: a collaboration with Earendil Labs on complex antibody and ADC programs, and a record showing at the 2026 Asia Pacific Biopharma Excellence Awards.\nSee our latest analysis for WuXi Biologics (Cayman).\nThose Earendil and awards announcements arrive as momentum has been mixed, with a 12.85% 1 month share price return decline, a 90 day share price return of 8.73%, and a 1 year total shareholder return of...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/a-look-at-wuxi-biologics-sehk2269-valuation-after-earendil-d","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/a-look-at-wuxi-biologics-sehk2269-valuation-after-earendil-d","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348735423.USD","LU0572944931.SGD","LU0181495838.USD","LU0979878070.USD","LU0819121731.USD","LU0327786744.USD","LU0348825331.USD","LU0320764599.SGD","02269","LU0856984785.SGD","LU1242518931.SGD","DCF","LU0516422952.EUR","LU0516423091.SGD","LU1880383366.USD","LU0708995583.HKD","LU1688375341.USD","LU0516423174.USD","BK1141","LU0516422440.USD","LU0140636845.USD","LU0588546209.SGD","LU3063872942.SGD","SG9999002463.SGD","LU0039217434.USD","LU0417516738.SGD","LU0456827905.SGD","LU0359201612.USD","BK1589","LU0052750758.USD","LU0326950275.SGD","LU0516422366.SGD","LU0823426308.USD","LU0043850808.USD","LU2039709279.SGD","LU1720050803.USD","SG9999002562.SGD","LU1794554557.SGD","LU0359202008.SGD","IE00B0JY6N72.USD","BK1610","LU0051755006.USD","LU0307460666.USD","LU0456846285.SGD","LU0823426480.USD","LU0417516902.SGD","LU1242518857.USD","BK1521","BK1576"],"gpt_icon":0},{"id":"2619241001","title":"WuXi Biologics Awards And Earendil Deal Shape Biologics Valuation Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2619241001","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619241001?lang=en_us&edition=fundamental","pubTime":"2026-03-14 19:35","pubTimestamp":1773488154,"startTime":"0","endTime":"0","summary":"WuXi Biologics (Cayman) (SEHK:2269) received six company awards and two individual awards at the 2026 Asia Pacific Biopharma Excellence Awards.\nThe company entered a collaboration with Earendil Labs to co develop multiple novel antibody and antibody drug conjugate therapeutics.\n\nFor investors tracking contract research, development and manufacturing organizations, WuXi Biologics sits at the center of global demand for outsourced biologics work. The new Asia Pacific awards span development,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/wuxi-biologics-awards-and-earendil-deal-shape-biologics-valu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/wuxi-biologics-awards-and-earendil-deal-shape-biologics-valu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0708995583.HKD","LU0588546209.SGD","LU0456827905.SGD","SG9999002562.SGD","LU2039709279.SGD","LU0456846285.SGD","LU0856984785.SGD","LU0516422952.EUR","LU0572944931.SGD","LU1720050803.USD","LU1688375341.USD","LU0516423174.USD","SG9999002463.SGD","LU1242518931.SGD","LU0417516902.SGD","02269","LU0359201612.USD","BK1589","LU0359202008.SGD","LU0516422440.USD","LU1794554557.SGD","LU0516422366.SGD","LU0516423091.SGD","LU0348825331.USD","IE00B0JY6N72.USD","LU0823426308.USD","LU1242518857.USD","BK1610","LU0819121731.USD","LU0823426480.USD","LU0327786744.USD","LU0140636845.USD","LU0348735423.USD","BK1576","LU0417516738.SGD","LU3063872942.SGD","LU0181495838.USD","BK1521","LU0979878070.USD","LU0052750758.USD","LU0307460666.USD","LU0043850808.USD","LU1880383366.USD","LU0320764599.SGD","LU0039217434.USD","BK1141","LU0326950275.SGD","LU0051755006.USD"],"gpt_icon":0},{"id":"2619195778","title":"WuXi XDC extends BioDlink cash offer deadline to March 27 after 47% share acceptances","url":"https://stock-news.laohu8.com/highlight/detail?id=2619195778","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619195778?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:33","pubTimestamp":1773397994,"startTime":"0","endTime":"0","summary":"BioDlink is seeking to acquire all shares of WuXi XDC it does not already own and to cancel all outstanding share options. As of 16:00 Hong Kong time on March 13, valid acceptances had been received for 359.63 million shares, representing 47% of WuXi XDC’s issued share capital and voting rights. Valid acceptances had also been received for 6.51 million share options, representing 85% of outstanding options. The offer deadline was extended to March 27 after the acceptance condition, which requires BioDlink to reach at least 60% of voting rights, was not met by the initial closing date. Three shareholders have agreed to tender a combined 104.04 million shares by March 17 following the extension.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal adv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL5gR6V3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0039217434.USD","LU0348825331.USD","LU1242518857.USD","SG9999002463.SGD","LU0417516738.SGD","LU0572944931.SGD","SG9999014674.SGD","02268","LU2488822045.USD","BK1521","LU0823426308.USD","LU0140636845.USD","LU0348735423.USD","LU0327786744.USD","LU0456827905.SGD","LU0856984785.SGD","LU1242518931.SGD","LU0359201612.USD","LU0979878070.USD","LU1880383366.USD","LU0417516902.SGD","02269","BK1610","LU0456846285.SGD","LU0819121731.USD","LU0823426480.USD","LU1688375341.USD","LU0516422440.USD","LU0516422366.SGD","BK1589","LU0181495838.USD","LU1720050803.USD","LU2039709279.SGD","LU0588546209.SGD","LU0359202008.SGD","LU0516423174.USD","LU0043850808.USD","IE00B0JY6N72.USD","LU0051755006.USD","LU0326950275.SGD","BK1576","LU0516423091.SGD","LU0307460666.USD","LU3063872942.SGD","LU0516422952.EUR","LU0052750758.USD","LU0320764599.SGD","LU1794554557.SGD","SG9999002562.SGD","BK1141"],"gpt_icon":0},{"id":"2619416789","title":"Wuxi Biologics (Cayman) Stock Falls 1.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2619416789","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619416789?lang=en_us&edition=fundamental","pubTime":"2026-03-13 16:43","pubTimestamp":1773391380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. slid 1.7% to 34.52 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.0% to 25465.60.This was the stock's third consecutive day of losses.Wuxi Biologics  Inc. closed 22% short of its 52-week high of HK$44.00, which the company reached Feb. 12.Trading volume totaled 17.4 million shares, compared to the 50-day average of 36.5 million shares.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","BK1141","LU0572944931.SGD","LU0181495838.USD","LU0456827905.SGD","LU0417516902.SGD","LU0051755006.USD","LU0516422952.EUR","LU0359202008.SGD","LU2039709279.SGD","LU0043850808.USD","IE00B0JY6N72.USD","LU1688375341.USD","LU0979878070.USD","LU0140636845.USD","SG9999002562.SGD","BK1521","LU0327786744.USD","LU0456846285.SGD","LU0856984785.SGD","LU0516423174.USD","LU0823426308.USD","LU1242518857.USD","LU0348735423.USD","LU0307460666.USD","LU1242518931.SGD","LU0348825331.USD","02269","BK1589","LU0588546209.SGD","LU0708995583.HKD","BK1610","LU1880383366.USD","LU0326950275.SGD","LU0516423091.SGD","LU1720050803.USD","LU0039217434.USD","LU0052750758.USD","LU1794554557.SGD","LU3063872942.SGD","LU0819121731.USD","SG9999002463.SGD","LU0823426480.USD","LU0320764599.SGD","LU0417516738.SGD","LU0516422366.SGD","LU0359201612.USD","LU0516422440.USD"],"gpt_icon":0},{"id":"1101142699","title":"CANBRIDGE-B Shares Climb Over 4% Following Completion of Share Placement to WuXi Biologics Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=1101142699","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101142699?lang=en_us&edition=fundamental","pubTime":"2026-03-13 14:48","pubTimestamp":1773384509,"startTime":"0","endTime":"0","summary":"CANBRIDGE-B (01228) saw its shares rise more than 4% in the afternoon session. At the time of writing, the stock was up 4%, trading at HK$2.6 with a turnover of HK$1.5938 million. The movement...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0181495838.USD","LU0588546209.SGD","LU1688375341.USD","LU0320764599.SGD","LU0359201612.USD","LU1720050803.USD","LU0039217434.USD","IE00B0JY6N72.USD","02269","LU0708995583.HKD","LU0456846285.SGD","LU0819121731.USD","LU0516422952.EUR","BK1161","LU0823426308.USD","LU1880383366.USD","LU0326950275.SGD","LU0516423174.USD","LU0856984785.SGD","BK1141","LU0456827905.SGD","SG9999002463.SGD","BK1589","LU3063872942.SGD","LU0052750758.USD","LU0348735423.USD","LU0823426480.USD","01228","BK4588","LU0359202008.SGD","LU0979878070.USD","LU2039709279.SGD","LU0051755006.USD","LU0327786744.USD","LU0516422440.USD","LU0516422366.SGD","SG9999002562.SGD","LU1794554557.SGD","BK4585","VXUS","BK1610","LU0307460666.USD","LU0348825331.USD","BK1521","LU0043850808.USD","LU0417516738.SGD","LU0417516902.SGD","LU0516423091.SGD","LU1242518857.USD","LU1242518931.SGD","LU0572944931.SGD","LU0140636845.USD","BK1576"],"gpt_icon":0},{"id":"2619016852","title":"WuXi Biologics Signs Antibody Development Deal with Earendil Labs","url":"https://stock-news.laohu8.com/highlight/detail?id=2619016852","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619016852?lang=en_us&edition=fundamental","pubTime":"2026-03-13 13:19","pubTimestamp":1773379197,"startTime":"0","endTime":"0","summary":"WuXi Biologics (Cayman) (HKG:2269) said it entered a collaboration with Earendil Labs to support the development and manufacturing of multiple bispecific and multispecific antibodies and antibody-drug","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0039217434.USD","LU0348825331.USD","LU1242518857.USD","SG9999002463.SGD","LU0417516738.SGD","LU0572944931.SGD","BK1521","LU0823426308.USD","LU0140636845.USD","LU0348735423.USD","LU0327786744.USD","LU0456827905.SGD","LU0856984785.SGD","LU1242518931.SGD","LU0359201612.USD","LU0979878070.USD","LU1880383366.USD","LU0417516902.SGD","02269","BK1610","LU0456846285.SGD","LU0819121731.USD","LU0823426480.USD","LU1688375341.USD","LU0516422440.USD","LU0516422366.SGD","BK1589","LU0181495838.USD","LU1720050803.USD","LU2039709279.SGD","LU0588546209.SGD","LU0359202008.SGD","LU0516423174.USD","LU0043850808.USD","IE00B0JY6N72.USD","LU0051755006.USD","LU0326950275.SGD","LU0708995583.HKD","BK1576","LU0516423091.SGD","LU0307460666.USD","LU3063872942.SGD","LU0516422952.EUR","LU0052750758.USD","LU0320764599.SGD","LU1794554557.SGD","SG9999002562.SGD","BK1141"],"gpt_icon":0},{"id":"2618912591","title":"Wuxi Biologics (Cayman) Stock Slips 1.4% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2618912591","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618912591?lang=en_us&edition=fundamental","pubTime":"2026-03-11 16:32","pubTimestamp":1773217920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. shed 1.4% to 36.10 Hong Kong dollars on what proved to be an all-around poor trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.2% to 25898.76.Wuxi Biologics  Inc. closed 18% short of its 52-week high of HK$44.00, which the company reached Feb. 12.Trading volume totaled 15.5 million shares, compared to the 50-day average of 36.2 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","LU0708995583.HKD","LU0516423091.SGD","LU0516422366.SGD","LU0140636845.USD","LU0320764599.SGD","LU0326950275.SGD","LU0327786744.USD","LU0348735423.USD","LU0516422952.EUR","LU0856984785.SGD","SG9999002463.SGD","LU0052750758.USD","LU1720050803.USD","LU1880383366.USD","LU3063872942.SGD","02269","LU0043850808.USD","LU0417516902.SGD","LU0516422440.USD","LU1688375341.USD","LU2039709279.SGD","LU0823426308.USD","LU0456827905.SGD","LU0456846285.SGD","LU0516423174.USD","LU0051755006.USD","LU0307460666.USD","LU0359201612.USD","LU0359202008.SGD","IE00B0JY6N72.USD","LU0572944931.SGD","LU0819121731.USD","LU1794554557.SGD","LU0039217434.USD","LU0823426480.USD","LU0181495838.USD","LU1242518857.USD","LU1242518931.SGD","BK1141","BK1576","BK1589","SG9999002562.SGD","LU0588546209.SGD","BK1610","LU0417516738.SGD","LU0348825331.USD","LU0979878070.USD"],"gpt_icon":0},{"id":"2618962996","title":"CANbridge Pharmaceuticals Nets HK$199 Million via Share Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2618962996","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618962996?lang=en_us&edition=fundamental","pubTime":"2026-03-11 09:42","pubTimestamp":1773193360,"startTime":"0","endTime":"0","summary":"CANbridge Pharmaceuticals  said it completed the placement of 84 million new shares at HK$2.38 each, raising net proceeds of about HK$199 million, according to a Wednesday Hong Kong bourse filing.The shares were subscribed by WuXi Biologics HealthCare Venture, a Hong Kong-based limited partnership indirectly wholly owned by WuXi Biologics .The proceeds will be used mainly to settle trade payables, support research and development for its pipeline, and fund working capital and registration maintenance for commercialized products, the company said.Separately, CANbridge said certain license agreements with WuXi Biologics will constitute continuing connected transactions after the subscription completion, as the subscriber has become a substantial shareholder.The agreements cover licenses for drug candidates including CAN103, CAN104, CAN105 and CAN106, which target rare diseases such as Gaucher disease, Fabry disease and hemophilia A, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320764599.SGD","LU0516423174.USD","LU2039709279.SGD","BK1141","LU0140636845.USD","BK1521","LU0348825331.USD","02269","LU0516422366.SGD","LU0052750758.USD","IE00B0JY6N72.USD","LU0456846285.SGD","LU0359201612.USD","LU0819121731.USD","BK1161","LU0417516902.SGD","LU1880383366.USD","BK1610","LU0348735423.USD","LU0979878070.USD","LU0327786744.USD","LU0856984785.SGD","LU0516422952.EUR","LU1242518931.SGD","LU1720050803.USD","LU0417516738.SGD","LU0039217434.USD","01228","LU1794554557.SGD","LU0307460666.USD","LU0588546209.SGD","SG9999002562.SGD","LU1242518857.USD","LU0326950275.SGD","LU1688375341.USD","LU0516422440.USD","BK1589","LU3063872942.SGD","LU0051755006.USD","BK1576","LU0043850808.USD","LU0823426308.USD","LU0516423091.SGD","LU0572944931.SGD","LU0708995583.HKD","LU0823426480.USD","SG9999002463.SGD","LU0359202008.SGD","LU0181495838.USD","LU0456827905.SGD"],"gpt_icon":0},{"id":"2618646183","title":"Wuxi Biologics (Cayman) Stock Sheds 2.5% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2618646183","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618646183?lang=en_us&edition=fundamental","pubTime":"2026-03-09 16:32","pubTimestamp":1773045120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. shed 2.5% to 35.42 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.4% to 25408.46.The stock's fall snapped a two-day winning streak.Wuxi Biologics  Inc. closed 20% below its 52-week high of HK$44.00, which the company reached Feb. 12.Trading volume totaled 37.3 million shares, compared to the 50-day average of 36.7 million shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","BK1576","LU0307460666.USD","02269","LU0819121731.USD","LU0516422952.EUR","LU0417516738.SGD","LU0039217434.USD","LU0979878070.USD","LU0052750758.USD","LU0516422366.SGD","LU1720050803.USD","LU0516422440.USD","LU0348735423.USD","LU2039709279.SGD","LU0856984785.SGD","LU1880383366.USD","LU0708995583.HKD","BK1521","LU0572944931.SGD","LU0043850808.USD","LU1688375341.USD","BK1589","LU0326950275.SGD","LU0588546209.SGD","LU1242518857.USD","LU3063872942.SGD","LU0051755006.USD","SG9999002562.SGD","LU0456827905.SGD","LU0359202008.SGD","LU0181495838.USD","LU0320764599.SGD","SG9999002463.SGD","LU0516423091.SGD","BK1610","LU0140636845.USD","LU0359201612.USD","LU1242518931.SGD","LU0823426308.USD","LU0327786744.USD","LU0456846285.SGD","LU1794554557.SGD","LU0823426480.USD","LU0516423174.USD","LU0417516902.SGD","LU0348825331.USD","IE00B0JY6N72.USD"],"gpt_icon":0},{"id":"1145157152","title":"WuXi Bio (02269) Publishes Monthly Return for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1145157152","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145157152?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:03","pubTimestamp":1772633002,"startTime":"0","endTime":"0","summary":"WuXi Biologics (Cayman) Inc. reported no changes to its share structure or treasury shares in February 2026. Authorized share capital remained at US$50,000, representing 6,000,000,000 ordinary shares...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"gpt_icon":0},{"id":"2616580121","title":"Wuxi Biologics (Cayman) Stock Falls 4.6% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2616580121","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616580121?lang=en_us&edition=fundamental","pubTime":"2026-03-04 16:30","pubTimestamp":1772613000,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. slid 4.6% to 35.30 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 2.0% to 25249.48.This was the stock's third consecutive day of losses.Wuxi Biologics  Inc. closed 20% short of its 52-week high of HK$44.00, which the company reached Feb. 12.Trading volume totaled 51.3 million shares, compared to the 50-day average of 35.3 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0979878070.USD","LU1720050803.USD","LU0819121731.USD","LU0348825331.USD","LU0417516738.SGD","LU0307460666.USD","LU0516422366.SGD","LU1794554557.SGD","LU0320764599.SGD","LU0708995583.HKD","LU0588546209.SGD","LU1242518857.USD","LU1688375341.USD","LU0140636845.USD","LU0516423091.SGD","LU0327786744.USD","BK1521","LU0051755006.USD","LU0052750758.USD","LU0417516902.SGD","LU0348735423.USD","02269","BK1589","LU0516423174.USD","SG9999002562.SGD","IE00B0JY6N72.USD","LU0456846285.SGD","LU0359201612.USD","LU0823426308.USD","LU0181495838.USD","LU3063872942.SGD","LU0516422952.EUR","LU1880383366.USD","LU0823426480.USD","LU0456827905.SGD","LU0516422440.USD","LU0039217434.USD","LU0359202008.SGD","SG9999002463.SGD","BK1610","LU2039709279.SGD","BK1141","LU0043850808.USD","LU0572944931.SGD","LU0326950275.SGD","LU0856984785.SGD","LU1242518931.SGD","BK1576"],"gpt_icon":0},{"id":"2616381992","title":"Wuxi Biologics (Cayman) Stock Slides 3.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2616381992","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616381992?lang=en_us&edition=fundamental","pubTime":"2026-03-02 16:32","pubTimestamp":1772440320,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. slid 3.7% to 38.74 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 2.1% to 26059.85.Wuxi Biologics  Inc. closed 12% below its 52-week high of HK$44.00, which the company reached Feb. 12.Trading volume totaled 38.3 million shares, compared to the 50-day average of 35.0 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","LU0823426308.USD","LU0856984785.SGD","LU1242518931.SGD","LU0326950275.SGD","LU0417516902.SGD","LU0516422440.USD","LU3063872942.SGD","LU0456827905.SGD","LU0708995583.HKD","LU0348735423.USD","BK1521","LU0359202008.SGD","LU0043850808.USD","LU0051755006.USD","LU0456846285.SGD","LU1720050803.USD","BK1141","BK1576","LU0819121731.USD","LU0039217434.USD","LU0516423091.SGD","LU0181495838.USD","LU0516422366.SGD","LU0516422952.EUR","LU0572944931.SGD","LU0307460666.USD","LU0140636845.USD","LU1242518857.USD","LU0327786744.USD","SG9999002463.SGD","LU0823426480.USD","LU1794554557.SGD","LU0979878070.USD","BK1610","LU0348825331.USD","LU1688375341.USD","IE00B0JY6N72.USD","02269","LU0516423174.USD","LU1880383366.USD","SG9999002562.SGD","LU2039709279.SGD","LU0052750758.USD","LU0417516738.SGD","LU0359201612.USD","LU0320764599.SGD","BK1589"],"gpt_icon":0},{"id":"2616809975","title":"WuXi Biologics Enters S&P Global Sustainability Yearbook 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616809975","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616809975?lang=en_us&edition=fundamental","pubTime":"2026-03-02 11:22","pubTimestamp":1772421741,"startTime":"0","endTime":"0","summary":"WuXi Biologics  Inc. said it was included in the S&P Global Sustainability Yearbook 2026 based on its performance in S&P Global’s 2025 Corporate Sustainability Assessment. The company said it ranked first in its industry and received a Top 1% CSA score, marking its fourth consecutive year in the Yearbook. WuXi Biologics also cited other ESG-related recognitions and ratings, including MSCI AAA, an EcoVadis Platinum Medal, inclusion in the Dow Jones Sustainability Indices, and CDP A List scores for climate change, water security and supplier engagement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL65dw3R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002463.SGD","LU0327786744.USD","LU1794554557.SGD","LU0572944931.SGD","LU0320765059.SGD","LU0289961442.SGD","LU1242518857.USD","LU1720050803.USD","LU0511384066.AUD","LU3063872942.SGD","LU0359202008.SGD","BK1589","LU0708995401.HKD","LU0516422366.SGD","LU0390134368.USD","LU0051755006.USD","LU0289739343.SGD","02269","LU0979878070.USD","BK4588","BK4585","LU0708995583.HKD","LU0326950275.SGD","LU0039217434.USD","IE00B0JY6N72.USD","BK1521","LU1804176565.USD","LU2095319765.USD","BK4112","LU0109391861.USD","LU1691799644.USD","SG9999002562.SGD","LU0672654240.SGD","LU2210149790.SGD","LU2210150020.SGD","MSCI","LU0516423091.SGD","LU0456846285.SGD","LU1267930730.SGD","LU2265009873.SGD","LU0052750758.USD","LU2039709279.SGD","LU0348825331.USD","LU0819121731.USD","LU0181495838.USD","LU0516422440.USD","LU0456827905.SGD","LU0320764599.SGD","LU0417516902.SGD","LU1688375341.USD"],"gpt_icon":0},{"id":"2616978809","title":"WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2616978809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616978809?lang=en_us&edition=fundamental","pubTime":"2026-03-02 11:22","pubTimestamp":1772421731,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA1L9MY2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPGI","LU1688375341.USD","LU2764263039.SGD","LU2089284900.SGD","LU0516423091.SGD","IE00B0JY6N72.USD","LU0856984785.SGD","LU0342679015.USD","LU0359202008.SGD","BK1576","LU2271345857.HKD","LU1496350171.SGD","BK4534","LU1720050803.USD","LU2506951958.HKD","SG9999017495.SGD","LU2039709279.SGD","LU0588546209.SGD","LU1794554557.SGD","LU0819121731.USD","SG9999014914.USD","BK4548","LU0354030438.USD","LU0516423174.USD","LU0823417737.USD","LU0140636845.USD","LU1880383366.USD","BK1610","LU2028103732.USD","LU0985320562.USD","LU1363072403.SGD","SG9999001077.SGD","BK1141","LU0348735423.USD","LU0456846285.SGD","LU1989764748.USD","LU2265009873.SGD","LU0971096721.USD","BK1521","LU1989773731.SGD","LU1988902786.USD","02269","BK4581","LU0289960550.SGD","LU0307460666.USD","LU0823426308.USD","LU1242518931.SGD","BK4112","BK4566","BK4597"],"gpt_icon":0},{"id":"2614833447","title":"WuXi XDC Partners With Earendil Labs on WuXiTecan-2 ADC Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2614833447","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614833447?lang=en_us&edition=fundamental","pubTime":"2026-02-27 17:11","pubTimestamp":1772183517,"startTime":"0","endTime":"0","summary":"WuXi XDC Cayman Inc. has entered a strategic collaboration with Earendil Labs to accelerate development of next-generation antibody-drug conjugates using WuXi XDC’s proprietary WuXiTecan-2 payload-linker technology. WuXi XDC will grant Earendil Labs an exclusive global license for multiple targets and provide CMC development and manufacturing support, while Earendil Labs will lead further development, regulatory submissions, and commercialization. The deal could be worth up to about $885 million including upfront and milestone payments, plus tiered royalties on net sales.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL77YWl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516422366.SGD","SG9999002463.SGD","LU0456827905.SGD","IE00B0JY6N72.USD","LU0359201612.USD","LU0516423091.SGD","BK1589","LU0819121731.USD","LU0051755006.USD","LU0856984785.SGD","LU0140636845.USD","LU1242518931.SGD","LU0359202008.SGD","LU3063872942.SGD","LU0327786744.USD","LU0708995583.HKD","LU0456846285.SGD","LU1720050803.USD","LU1880383366.USD","BK1521","LU0326950275.SGD","LU0516422952.EUR","LU0572944931.SGD","LU0307460666.USD","LU0043850808.USD","02268","LU0516423174.USD","LU0979878070.USD","LU0348825331.USD","LU0588546209.SGD","02269","LU0320764599.SGD","LU0823426308.USD","BK1141","LU0039217434.USD","LU2039709279.SGD","LU1242518857.USD","BK1610","LU1794554557.SGD","LU0417516738.SGD","LU0181495838.USD","LU0417516902.SGD","SG9999002562.SGD","LU1688375341.USD","LU0516422440.USD","SG9999014674.SGD","LU0823426480.USD","LU0348735423.USD","BK1576","LU0052750758.USD"],"gpt_icon":0},{"id":"2614801688","title":"Wuxi Biologics (Cayman) Stock Rises 5.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2614801688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614801688?lang=en_us&edition=fundamental","pubTime":"2026-02-27 16:30","pubTimestamp":1772181000,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. rose 5.1% to 40.22 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.9% to 26630.54.Wuxi Biologics  Inc. closed 8.6% short of its 52-week high of HK$44.00, which the company achieved Feb. 12.Trading volume totaled 40.3 million shares, compared to the 50-day average of 34.6 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","LU0708995583.HKD","LU0516423091.SGD","LU0516422366.SGD","LU0140636845.USD","LU0320764599.SGD","LU0326950275.SGD","LU0327786744.USD","LU0348735423.USD","LU0516422952.EUR","LU0856984785.SGD","SG9999002463.SGD","LU0052750758.USD","LU1720050803.USD","LU1880383366.USD","LU3063872942.SGD","02269","LU0043850808.USD","LU0417516902.SGD","LU0516422440.USD","LU1688375341.USD","LU2039709279.SGD","LU0823426308.USD","LU0456827905.SGD","LU0456846285.SGD","LU0516423174.USD","LU0051755006.USD","LU0307460666.USD","LU0359201612.USD","LU0359202008.SGD","IE00B0JY6N72.USD","LU0572944931.SGD","LU0819121731.USD","LU1794554557.SGD","LU0039217434.USD","LU0823426480.USD","LU0181495838.USD","LU1242518857.USD","LU1242518931.SGD","BK1141","BK1576","BK1589","SG9999002562.SGD","LU0588546209.SGD","BK1610","LU0417516738.SGD","LU0348825331.USD","LU0979878070.USD"],"gpt_icon":0},{"id":"1160659957","title":"Tech-Heavy Index Slides Over 1% as AI Hardware Stocks Retreat, Rare Earths Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1160659957","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160659957?lang=en_us&edition=fundamental","pubTime":"2026-02-27 10:16","pubTimestamp":1772158579,"startTime":"0","endTime":"0","summary":"AI hardware stocks experienced a collective adjustment, influenced by a significant overnight decline in NVIDIA shares, which plunged 5.7% intraday, marking their largest single-day drop in three...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"7a755cbafd825462988989b314d464b7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["512880","510880","WXXWY","BK4588","399001","02269","000300.SH","515890","159967","BK4585","000905.SH","000688.SH","510300","512510","NVDA"],"gpt_icon":1},{"id":"2614670901","title":"Wuxi Biologics (Cayman) Stock Rallies 1.6% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2614670901","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614670901?lang=en_us&edition=fundamental","pubTime":"2026-02-25 16:33","pubTimestamp":1772008380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. rose 1.6% to 41.36 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.7% to 26765.72.Wuxi Biologics  Inc. closed 6.0% below its 52-week high of HK$44.00, which the company reached Feb. 12.Trading volume totaled 15.6 million shares, compared to the 50-day average of 34.7 million shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0051755006.USD","LU3063872942.SGD","LU0181495838.USD","LU0359201612.USD","LU1688375341.USD","LU0516422366.SGD","LU0326950275.SGD","LU0359202008.SGD","LU1794554557.SGD","BK1521","LU0417516738.SGD","LU0516423091.SGD","LU0052750758.USD","LU0823426480.USD","LU0348735423.USD","LU0348825331.USD","LU0819121731.USD","LU0516423174.USD","LU1720050803.USD","BK1589","LU1242518857.USD","LU0043850808.USD","LU0856984785.SGD","LU0456827905.SGD","02269","LU1880383366.USD","LU0588546209.SGD","LU0417516902.SGD","LU0516422440.USD","LU0307460666.USD","LU0039217434.USD","LU0572944931.SGD","LU1242518931.SGD","LU0823426308.USD","LU0456846285.SGD","SG9999002562.SGD","BK1141","LU0320764599.SGD","LU0327786744.USD","BK1576","LU2039709279.SGD","LU0140636845.USD","IE00B0JY6N72.USD","BK1610","LU0979878070.USD","SG9999002463.SGD","LU0516422952.EUR","LU0708995583.HKD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxibiologics.com","stockEarnings":[{"period":"1week","weight":-0.0459},{"period":"1month","weight":-0.1265},{"period":"3month","weight":0.0738},{"period":"6month","weight":-0.1018},{"period":"1year","weight":0.3135},{"period":"ytd","weight":0.1113}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0263},{"period":"3month","weight":0.0157},{"period":"6month","weight":-0.0255},{"period":"1year","weight":0.0714},{"period":"ytd","weight":0.0093}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.052868},{"month":2,"riseRate":0.555556,"avgChangeRate":0.006907},{"month":3,"riseRate":0.555556,"avgChangeRate":0.003327},{"month":4,"riseRate":0.375,"avgChangeRate":-0.000625},{"month":5,"riseRate":0.5,"avgChangeRate":0.00166},{"month":6,"riseRate":0.625,"avgChangeRate":0.064583},{"month":7,"riseRate":0.666667,"avgChangeRate":0.081469},{"month":8,"riseRate":0.555556,"avgChangeRate":0.030253},{"month":9,"riseRate":0.666667,"avgChangeRate":0.056337},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.033632},{"month":11,"riseRate":0.444444,"avgChangeRate":0.025584},{"month":12,"riseRate":0.555556,"avgChangeRate":0.009161}],"exchange":"SEHK","name":"WUXI BIO","nameEN":"WUXI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"WUXI BIO(02269),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest WUXI BIO(02269) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"WUXI BIO,02269,WUXI BIO股票,WUXI BIO股票老虎,WUXI BIO股票老虎国际,WUXI BIO行情,WUXI BIO股票行情,WUXI BIO股价,WUXI BIO股市,WUXI BIO股票价格,WUXI BIO股票交易,WUXI BIO股票购买,WUXI BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"WUXI BIO(02269),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest WUXI BIO(02269) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}